Anavex Life Sciences Corp (AVXL)

[jimmy667]

I definitely agree with this anology of Arrowhead and Anavex. I got involved with ARWR between $13 and $17 in 2018 when it was clear to the those that did deep DD that they had the goods. Lucky to have spotted Anavex prior to the "market acceptance phase". ARWR rapid price appreciation was sentiment based in market acceptance. The charts of AVXL and ARWR are strikingly similar during the pre acceptance phase. AVXL is still in the pre acceptance phase. Arrowhead is a pioneer in gene silencing as opposed to gene editing therefore less unintended side effects that have crippled gene edit technologies.
Anavex has even greater potential than Arrowhead in my opinion.
Both are determined and focused companies. It took very little time for Arrowhead to start generating revenue and when it did one sees the hockey stick on the stock price chart. Anavex is approaching such an acceleration phase as well.
Anavex has almost unlimited potential as is being "market recognized" in Arrowhead. One would do well to observe the market cap of ARWR a few years ago to the market cap it sports today. Much like Avavex today it was unknown and poorly understood.
This will likely change in a Nidian style flashover possibly in less than one year. Arrowhead was volatile as well. All prerevenue Biotechs are.
Avavex is gaining footing carefully and deliberately that is why the dearth of flashy BIIB style PRs. All business of advancing clinical trials. Lazer focused.
Dr Christopher Missling on the record, "I see my primary duty as CEO of Anavex as the management of risk in the clinical trials". That does it for me. The primary focus should be none other.
Go Anavex>>>>>>>>